C12N 2740/15061
Methods of inactivation or attenuation
C12N2740/15061 (Methods of inactivation or attenuation) appears on 18 US grants and 35 published applications in this corpus.
Search patents in C12N- Granted patents
- 18
- Published applications
- 35
- Assignees
- 21
- Inventors
- 81
- Latest grant
- 2 Nov 2021
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 2 | 1 |
| 2002 | 0 | 0 |
| 2003 | 2 | 5 |
| 2004 | 2 | 2 |
| 2005 | 1 | 1 |
| 2006 | 1 | 1 |
| 2007 | 0 | 0 |
| 2008 | 1 | 1 |
| 2009 | 0 | 2 |
| 2010 | 0 | 2 |
| 2011 | 0 | 2 |
| 2012 | 2 | 2 |
| 2013 | 0 | 0 |
| 2014 | 2 | 1 |
| 2015 | 2 | 2 |
| 2016 | 1 | 0 |
| 2017 | 0 | 1 |
| 2018 | 1 | 0 |
| 2019 | 0 | 1 |
| 2020 | 0 | 0 |
| 2021 | 1 | 0 |
| 2022 | 0 | 5 |
| 2023 | 0 | 1 |
| 2024 | 0 | 3 |
| 2025 | 0 | 2 |
By publication year.
Subgroups
Granted patents
Recent patents
- Attenuated viruses useful for vaccines2 Nov 2021US 11,162,080 B2The Research Foundation for The State University of New York
- Methods of making modified viral genomes17 Jul 2018US 10,023,845 B2The Research Foundation for The State University of New York
- Attenuated viruses useful for vaccines25 Oct 2016US 9,476,032 B2The Research Foundation for The State University of New York
- Methods for treating spinal muscular atrophy24 Mar 2015US 8,986,935 B2PTC Therapeutics, Inc.
- Screening assays for compounds that modulate programmed ribosomal frameshifting13 Jan 2015US 8,932,818 B2PTC Therapeutics, Inc.
- Nucleic Acid Molecule, Vector, Recombinant Cells, and Drug for Treating Central Nervous System Disease18 Dec 2025US 2025/0381296 A1JCR Pharmaceuticals Co., Ltd.
- Lentiviral vector17 Apr 2025US 2025/0122528 A1Touchlight IP Limited
- Retargeted retroviral vectors resistant to vaccine-induced neutralization and compositions or methods of use thereof19 Sep 2024US 2024/0307555 A1The Broad Institute, Inc.
- Retargeted retroviral vectors and compositions or methods of use thereof5 Sep 2024US 2024/0294942 A1The Broad Institute, Inc.
- Attenuated viruses useful for vaccines11 Jul 2024US 2024/0228981 A1The Research Foundation for The State University of New York
Most cited
By later US patents
- Equine infectious anemia virus vectors18US 6,312,683 B1Oxford Biomedica (UK) Limited · 2001
- Attenuated viruses useful for vaccines13US 9,476,032 B2The Research Foundation for The State University of New York · 2016
- Methods for producing high titre vectors and compositions used in such methods8US 6,969,598 B2Oxford Biomedica (UK) Limited · 2005
- Attenuated lentivirus vectors expressing interferon6US 6,326,007 B1The Regents of the University of California · 2001
- Modified viral particles with immunogenic properties and reduced lipid content4US 7,407,662 B2Lipid Sciences, Inc. · 2008